MOLECULAR PARTNERS N news, videos and press releases
For more news please use our advanced search feature.
MOLECULAR PARTNERS N - More news...
MOLECULAR PARTNERS N - More news...
- Molecular Partners to hold three poster presentations at AACR 2025
- Molecular Partners Publishes Invitation to Annual General Meeting 2025
- Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
- Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call
- Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
- Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
- Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
- Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
- Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
- Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
- Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
- Molecular Partners Announces Pricing of $20 Million Underwritten Offering
- Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
- Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
- Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
- Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
- Molecular Partners Reports H1 2024 Corporate Highlights and Financials
- Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
- Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
- Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
- Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
- Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
- Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
- Life Science Cares Launches in Switzerland
- Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
- Molecular Partners Publishes Invitation to Annual General Meeting 2024
- Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
- Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
- Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
- Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
